1. Home
  2. OTLK

as of 02-17-2026 3:42pm EST

$0.42
$0.07
-13.86%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Founded: 2010 Country:
N/A
Employees: N/A City: ISELIN
Market Cap: 38.7M IPO Year: N/A
Target Price: $3.83 AVG Volume (30 days): 1.9M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.38 - $3.39 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 1425.11% Revenue Growth (next year): 129.89%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered OTLK Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 68.52%
68.52%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Outlook Therapeutics Inc. News

OTLK Breaking Stock News: Dive into OTLK Ticker-Specific Updates for Smart Investing

All OTLK News

Share on Social Networks: